APA (7th ed.) Citation

I, G., TF, J., LS, T., M, B., TF, H., LH, J., . . . C, Q. (2026). Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 44(18), 1687. https://doi.org/10.1200/JCO-25-02274

Chicago Style (17th ed.) Citation

I, Gögenur, et al. "Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 44, no. 18 (2026): 1687. https://doi.org/10.1200/JCO-25-02274.

MLA (9th ed.) Citation

I, Gögenur, et al. "Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 44, no. 18, 2026, p. 1687, https://doi.org/10.1200/JCO-25-02274.